On August 10th 2023, Urogen Pharma ($NASDAQ:URGN) revealed their earnings results for the second quarter of FY2023, recording a total revenue of USD 21.1 million – a 27.3% rise compared to the same period last year. However, their net income was reported at USD -24.1 million, which is a decrease from the -26.7 million of the previous year.
GoodWhale has conducted an analysis of UROGEN PHARMA‘s financials, resulting in a low health score of 2/10 for cashflows and debt. This indicates that UROGEN PHARMA is less likely to sustain future operations in times of crisis. According to the Star Chart, UROGEN PHARMA is classified as a ‘cheetah’, meaning that the company has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Given its strong growth and weak asset, dividend, and profitability, UROGEN PHARMA would likely be of interest to investors who are looking for high returns with high risk. These investors are typically willing to trade stability for the chance at a high return on their investment. They may also be interested in the possibility that UROGEN PHARMA could become a stable and profitable company over time. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Urogen Pharma. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Urogen Pharma. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Urogen Pharma. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Urogen Pharma are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The competition between UroGen Pharma Ltd and its competitors is fierce. Each company is vying for market share in the lucrative pharmaceutical market. The competition is intense and the stakes are high. Each company is trying to develop new and innovative products that will appeal to consumers. They are also trying to create a brand that will be recognizable and trusted by consumers.
– PhaseBio Pharmaceuticals Inc ($NASDAQ:PHAS)
Aptose Biosciences Inc is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapeutic drugs for the treatment of cancer. It focuses on developing next-generation therapies that target the underlying cause of cancer. The company was founded by William G. Rice, John D. Lewis, and Robert J. Keith on February 23, 1999 and is headquartered in Toronto, Canada.
– Puma Biotechnology Inc ($NASDAQ:PBYI)
Puma Biotechnology Inc is a development stage biopharmaceutical company. The company focuses on the development and commercialization of novel cancer therapies. Puma’s lead product candidate, neratinib, is an oral, irreversible pan-ErbB inhibitor. The company is also developing PB272, an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor 2 for the treatment of patients with HER2-positive breast cancer.
– Verrica Pharmaceuticals Inc ($NASDAQ:VRCA)
Verrica Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing and commercializing treatments for skin diseases. The company’s lead product candidate is VP-102, a topical therapy for the treatment of molluscum contagiosum, a viral skin disease. Verrica’s product pipeline also includes VP-103, a topical therapy for the treatment of common warts, and VP-104, a topical therapy for the treatment of plantar warts.
Verrica Pharmaceuticals Inc has a market cap of 120.41M as of 2022, a Return on Equity of -175.92%. The company’s lead product candidate is VP-102, a topical therapy for the treatment of molluscum contagiosum, a viral skin disease. Verrica’s product pipeline also includes VP-103, a topical therapy for the treatment of common warts, and VP-104, a topical therapy for the treatment of plantar warts.
The company’s focus on developing treatments for skin diseases gives it a potential competitive advantage in the pharmaceutical industry. However, the company’s negative ROE indicates that it is not yet profitable. Verrica will need to generate positive earnings in order to attract investors and grow its business.
Investing analysis of UROGEN PHARMA shows a 27.3% increase in total revenue for the second quarter of 2023 compared to the same period last year.
However, net income reported was USD -24.1 million, a decrease from the previous year of -26.7 million. Despite the growth in revenue, investors should be cautious about the company’s weak profit performance. Companies need to improve their bottom lines to remain attractive to potential investors and deliver sustainable returns over the long term. Investors should continue to monitor developments within the company to better assess its potential for future returns.